Clinical Trial Update: Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of venetoclax and tocilizumab for relapsed or refractory t(11;14) multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Tocilizumab (tocilizumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Emory University | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING